


Clinical Applications of Nasal High Flow (NHF) Therapy



Applications of NHF therapy

In each of these areas a suitable application for NHF therapy was demonstrated in the referenced studies. As always clinical judgment must be applied in each case to determine the appropriate therapy.



ESICM CLINICAL PRACTICE GUIDELINE FOR NASAL HIGH FLOW

Rochweg B, et al. Intensive Care Medicine. 2020.

The role for high flow nasal cannula as a respiratory support strategy in adults

Icon: Head with nasal cannula	Icon: Head with nasal cannula	Icon: Head with nasal cannula	Icon: Head with nasal cannula
<p>Acute hypoxemic respiratory failure</p> <p>NHF is preferred to conventional oxygen therapy (COT) for patients with hypoxemic respiratory failure.</p>	<p>Peri-intubation</p> <p>No recommendation is made regarding use of NHF in the peri-intubation period.</p> <p>NHF during intubation should be continued for patients who are already receiving NHF.</p>	<p>Post-extubation respiratory failure</p> <p>NHF is preferred to COT following extubation in patients with any high-risk feature who were intubated for >24 hours.</p> <p>NIPPV is preferred to NHF in patients who would normally be extubated to NIPPV.</p>	<p>Post-operative</p> <p>NHF is preferred to COT in high risk and/or obese patients undergoing cardiac or thoracic surgery to prevent respiratory failure in the immediate postoperative period.</p> <p>Prophylactic NHF to prevent respiratory failure in other postoperative patients is not recommended.</p>
STRONG RECOMMENDATION	CONTINUE NHF	CONDITIONAL RECOMMENDATION	CONDITIONAL RECOMMENDATION

Rochweg B, et al. Intensive Care Med. 2019.



Patients with acute hypoxemic respiratory failure

NHF vs COT

NHF is associated with a lower risk of requiring intubation

RR=0.85; 95% CI 0.74-0.99

NHF is associated with a decreased escalation of oxygen therapy

RR=0.71; 95% CI 0.51-0.98

No difference in mortality between NHF and COT

RR=0.94; 95% CI 0.67-1.31

100% of the analyzed studies used F&P Optiflow NHF systems | Total: n = 446 | Randomized controlled trial: n = 9

Chaudhuri D, et al. Chest. 2020.



Preventing intubation in post-operative patients

NHF vs COT

NHF is associated with a lower risk of requiring intubation

RR=0.32; 95% CI 0.12-0.88

NHF is associated with a decreased escalation of respiratory support

RR=0.54; 95% CI 0.31-0.94

91% of the analyzed studies used F&P Optiflow NHF systems | Total: n = 650 | Randomized controlled trial: n = 11

Granton D, et al. Critical Care Medicine. 2020.



Critically ill adult patients immediately post-extubation

NHF vs COT

NHF is associated with a decreased rate of reintubation

RR=0.46; 95% CI 0.3-0.7

NHF is associated with decreased post-extubation respiratory failure

RR=0.52; 95% CI 0.3-0.91

NHF may decrease use of NIV

RR=0.64 CI 0.34-1.22

NHF may decrease hospital LoS

-0.98 days CI -2.96-0.21


NHF vs NIV

NHF may reduce ICU and hospital LoS

*ICU: -0.99 days (-1.68, -0.30)
Hospital -3 days (-6.24, 0.24)*

100% of the analyzed studies used F&P Optiflow NHF systems | Total: n = 492 | Randomized controlled trial: n = 8

SELECTED CLINICAL EVIDENCE FOR APPLICATIONS OF NHF THERAPY



REFERENCES

Bell N, Hutchinson CL, Green TC, et al. Randomised control trial of humidified high flow nasal cannulae versus standard oxygen in the emergency department. *Emerg Med Australas*. 2015 Dec; 27(6):537-41.

Bonnet N, Martin O, Boubaya M, et al. High flow nasal oxygen therapy to avoid invasive mechanical ventilation in SARS-CoV-2 pneumonia: a retrospective study. *Ann Intensive Care* 11, 37 (2021).

Calligaro G, Lalla U, Audley G, et al. The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study. *EClinicalMedicine* 2020.

Chaudhuri D, Granton D, Wang DX, et al. High-Flow Nasal Cannula in the Immediate Postoperative Period: A Systematic Review and Meta-analysis. *Chest*. 2020;158(5):1934-1946.

Frat J, Thille A, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med*. 2015; 1-12.

Frat J, Ricard J, Quenot J, et al. Non-invasive ventilation versus high-flow nasal cannula oxygen therapy with apnoeic oxygenation for preoxygenation before intubation of patients with acute hypoxaemic respiratory failure: a randomised, multicentre, open-label trial. *Lancet Respir Med*. 2019 Apr;7(4): 303-312.

Granton D, Chaudhuri D, Wang D, et al. High-Flow Nasal Cannula Compared With Conventional Oxygen Therapy or Noninvasive Ventilation Immediately Postextubation: A Systematic Review and Meta-Analysis. *Crit Care Med*. 2020;48(11):e1129-e1136.

Guy T, Créac'hacdec A, Ricordel C, et al. High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU. *Eur Respir J*. 2020;2001154.

Hernández G, Vaquero C, González P, et al. Effect of postextubation high-flow nasal cannula vs conventional oxygen therapy on reintubation in low-risk patients. *JAMA*. 2016;315(13):1354.

Hernández G, Vaquero C, Colinas L, et al. Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients. *JAMA*. 2016;316(15):1565.

Jackson JA, Spilman SK, Kingery LK, et al. Implementation of High-Flow Nasal Cannula Therapy Outside the Intensive Care Setting. *Respiratory care*, respcare.07960. 25 Aug. 2020.

Miguel-Montanes R, Hajage D, Messika J, et al. Use of high-flow nasal cannula oxygen therapy to prevent desaturation during tracheal intubation of intensive care patients with mild-to-moderate hypoxemia. *Crit Care Med*. 2015;43(3):574-83.

Papachatzakis Y, Nikolaidis PT, Kontogiannis S, Trakada G. High-Flow Oxygen through Nasal Cannula vs. Non-Invasive Ventilation in Hypercapnic Respiratory Failure: A Randomized Clinical Trial. *International Journal of Environmental Research and Public Health* vol. 17,16 5994. 18 Aug. 2020.

Patel M, Gangemi A, Marron R, et al. Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure *BMJ Open Respiratory Research* 2020;7:e000650.

Rochweg B, Einav S, Chaudhuri D, et al. The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline. *Intensive Care Med*. 2020; 46(12):2226-2237.

Rochweg B, Granton D, Wang DX, et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. *Intensive Care Med*. 2019;45(5):563-572.

Spoletini G, Mega C, Pisani L, et al. High-flow nasal therapy vs standard oxygen during breaks off noninvasive ventilation for acute respiratory failure: A pilot randomized controlled trial. *J Crit Care*. 2018 Oct 5;48: 418-425.

Storgaard L, Hockey H, Laursen B, et al. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. *Int J Chron Obstruct Pulmon Dis*. 2018;13:1195-1205.

Tan, D, Walline, J, Ling, B et al. High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial. *Crit Care*, 2020; 24, 489.

Thille AW, Muller G, Gacouin A, et al. Effect of postextubation high-flow nasal oxygen with noninvasive ventilation vs high-low nasal oxygen alone on reintubation among patients at high risk of extubation failure: a randomized clinical trial. *JAMA* 2019.

Vianello A, Arcaro G, Molena B, et al. High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection. *Thorax*. 2020; 75:998-1000.

The contents of this document is intended exclusively for healthcare professionals and is not a substitute for the exercise of clinical judgement by an appropriately qualified healthcare professional. Prior to the use of any medical device product, healthcare professionals should refer to the User Instructions provided with the product.